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medication prescribed to treat it. Pain Management Index 
(PMI) is calculated by subtracting the patient-rated pain 
intensity score from the analgesic score. A negative PMI score 
( -3 to -1) indicated inadequate analgesic management. 
 
Results: 
 
58 patients were available for analysis, 51 males and 7 
females with median age of 54 years. 
Of these, 72.4% patients were stage III disease and 27.6% 
were stage IV. Majority were oral cavity primary (36.2%) 
followed by oropharynx (24.1%), larynx (22.2%) and 
hypopharynx (8.6%) 72% patients reported pain for 0-6 
months prior to study entry. On average, pain intensity 
measure before start of CCRT was 2.14(mild), 8.60( severe) 
at 3 weeks of RT, 6.01(moderate) at the end and 1.36(mild) 
at 3 months of follow-up.  
Mean score for Worst Pain intensity was 8.7 at 3 weeks of 
treatment.Patients who received opioids (mild/strong) before 
start of RT, at 3 weeks of treatment and at the end were 
6.91%, 20.69% and 10.34% respectively. Most common 
neuropathic pain descriptors chosen were- Aching (60.34%) 
and Burning (36.21%); nociceptive words chosen were- 
Throbbing (84.48%), Shooting (37.93%) and Tender (34.48%) 
and Affective descriptors were Tiring (70.68%) and Nagging 
(55.17%).  
> 50% pain relief with the analgesics prescribed was attained 
by 70.68% patients before start of therapy, 65.51% and 
82.76% at 3 weeks and end of therapy respectively.Based on 
PMI, during radiation 44.83% (26/58) and at the end of 
therapy 34.48% (20/58) patients received undertreatment for 
their level of pain intensity. 
Conclusions: Inadequate pain management appears to be a 
persistent problem for patients undergoing radiotherapy. 
Clinical management of both nociceptive as well as 
neuropathic components and more appropriate and judicious 
use of strong opioids can contribute to improved pain relief. 
Future educational efforts should therefore target radiation 
oncologists as an important resource for treatment of cancer 
pain. 
   
PO-0770   
Stereotactic radiotherapy versus surgery: comparison of 
survival in lung metastases from colo-rectal cancer 
A.R. Filippi1, F. Guerrera2, S. Badellino1, M. Ceccarelli3, A. 
Castiglione3, A. Guarneri4, R. Spadi5, P. Racca5, G. Ciccone3, 
U. Ricardi1, E. Ruffini2 
1University of Torino, Department of Oncology, Torino, Italy  
2University of Torino, Department of Surgical Sciences, 
Torino, Italy  
3Città della Salute e della Scienza, Unit of Clinical 
Epidemiology, Torino, Italy  
4Città della Salute e della Scienza, Radiation Oncology, 
Torino, Italy  
5Città della Salute e della Scienza, Medical Oncology - 
Colorectal Cancer Unit, Torino, Italy  
 
Purpose/Objective: Lung metastasectomy and Stereotactic 
Ablative Radiotherapy (SABR) are proposed to selected stage 
IV oligo-metastatic colo-rectal cancer (CRC) patients in 
absence of clear evidence of superiority of any of the two 
approaches. Aim of the present retrospective cohort study 
was to perform an explorative comparison of the two 
treatments (SABR vs. surgery) on overall survival.  
Materials and Methods: All patients who consecutively were 
referred to the Thoracic Surgery Unit and underwent surgery 
(n=180) or to the Radiation Oncology Unit an underwent SABR 
(n=28) as first local therapy for lung metastases between 
2005 and 2012 were considered for analysis. SABR was 
delivered with a single fraction of 26 Gy prescribed at the 
80% isodose. Surgery consisted in nonanatomic wedge 
resections. Overall survival functions according to treatment 
were calculated using Kaplan-Meier method and compared 
using Log-rank test. Crude and adjusted hazard ratios 
(controlling for age, gender, comorbidities, CEA levels and 
disease-free interval) were estimated by Cox models. A 
sensitivity analysis was also performed by using the 
propensity score (inverse probability treatment weighting 
method). 
Results: Patients receiving SABR were older and were treated 
more recently, had less lung metastases, while comorbidities 
and size of the treated lesions were similar in the two 
groups. Median follow-up were 36 months for the surgical 
cohort and 30 months for the SABR cohort. Overall survival at 
1 and 2 years were 0.89 and 0.77 for SABR group and 0.94 
and 0.80 for surgery group (log-rank test p-value=0.24), 
thereafter the survival seems to be lower for the SABR group 
(fig1). After adjustement, the HR of SABR vs surgery was 
1.51(95%CI:0.75-3.04; p=0.24). These results were confirmed 
in the sensitivity analysis. 
Conclusions: Results of the present study shows that overall 
survival probability after SABR is similar to surgery, at least 
for the first two years from treatment. The survival 
projection is limited afterwards as the follow-up of the SABR 
cohort is shorter. These results suggest that SABR should be 
included as a local treatment option in a randomized trial. 
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